No Data
ITeos Therapeutics (NASDAQ:ITOS): Harnessing the Power of Immunotherapy
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
ITeos Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ITeos Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on ITeos Therapeutics, Raises Price Target to $46
ITeos Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 156.98% HC Wainwright & Co. $44 → $46 Maintains Buy 03/12/2024 50.84% JP Morgan $29 → $27 Maint
ITeos Therapeutics Shares Surge 47% After Promising Tumor Treatment Data
By Ben Glickman Shares of iTeos Therapeutics rose sharply after the company said one of its tumor treatment clinical trials had shown promising interim results. The stock was up 47% to $17.86 in Fri